Tags

Type your tag names separated by a space and hit enter

Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
Headache. 2019 07; 59 Suppl 2:20-32.H

Abstract

Calcitonin-gene-related peptide (CGRP), a neuropeptide broadly distributed in neuronal and non-neuronal regions throughout the body, plays a fundamental role in migraine and cluster headache (CH) pathophysiology. CGRP functional blockade alleviates neurogenic inflammation and reduces pain pathway sensitization. Two types of CGRP function-blocking modalities, monoclonal antibodies (MAbs), and small molecules (gepants), have been designed to target the CGRP ligands and CGRP receptors. In this narrative review, we summarized the latest clinical trials on gepants and CGRP function-blocking MAbs for migraine and CH prevention. At the time of writing, newer gepants are currently under Federal Drug Administration (FDA) review for migraine management, but there is no study yet on the usage of gepants for CH. Erenumab, fremanezumab, and galcanezumab have been approved by the FDA for migraine prevention while eptinezumab is under FDA review. CGRP MAbs are as effective as and more tolerable than conventional migraine preventives. For CH prevention, galcanezumab has shown some promising findings and was recently approved for use in episodic cluster prevention. CGRP function-blocking therapy not only demonstrates high efficacy and superior safety profile, but also improves headache frequency and quality of life. Convenient monthly dosing for the MAbs can further improve medication adherence, hence better headache control. With CGRP function-blocking therapy showing efficacy even in individuals who failed other preventives, it has become an exciting new therapeutic option in the field of migraine and CH.

Authors+Show Affiliations

Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA.Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA.Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31291020

Citation

Yuan, Hsiangkuo, et al. "Targeting CGRP for the Prevention of Migraine and Cluster Headache: a Narrative Review." Headache, vol. 59 Suppl 2, 2019, pp. 20-32.
Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. Headache. 2019;59 Suppl 2:20-32.
Yuan, H., Spare, N. M., & Silberstein, S. D. (2019). Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. Headache, 59 Suppl 2, 20-32. https://doi.org/10.1111/head.13583
Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the Prevention of Migraine and Cluster Headache: a Narrative Review. Headache. 2019;59 Suppl 2:20-32. PubMed PMID: 31291020.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. AU - Yuan,Hsiangkuo, AU - Spare,Nicole M, AU - Silberstein,Stephen D, PY - 2019/06/15/accepted PY - 2019/7/11/entrez PY - 2019/7/11/pubmed PY - 2020/7/21/medline KW - calcitonin gene-related peptide KW - cluster headache KW - gepant KW - migraine KW - monoclonal antibody SP - 20 EP - 32 JF - Headache JO - Headache VL - 59 Suppl 2 N2 - Calcitonin-gene-related peptide (CGRP), a neuropeptide broadly distributed in neuronal and non-neuronal regions throughout the body, plays a fundamental role in migraine and cluster headache (CH) pathophysiology. CGRP functional blockade alleviates neurogenic inflammation and reduces pain pathway sensitization. Two types of CGRP function-blocking modalities, monoclonal antibodies (MAbs), and small molecules (gepants), have been designed to target the CGRP ligands and CGRP receptors. In this narrative review, we summarized the latest clinical trials on gepants and CGRP function-blocking MAbs for migraine and CH prevention. At the time of writing, newer gepants are currently under Federal Drug Administration (FDA) review for migraine management, but there is no study yet on the usage of gepants for CH. Erenumab, fremanezumab, and galcanezumab have been approved by the FDA for migraine prevention while eptinezumab is under FDA review. CGRP MAbs are as effective as and more tolerable than conventional migraine preventives. For CH prevention, galcanezumab has shown some promising findings and was recently approved for use in episodic cluster prevention. CGRP function-blocking therapy not only demonstrates high efficacy and superior safety profile, but also improves headache frequency and quality of life. Convenient monthly dosing for the MAbs can further improve medication adherence, hence better headache control. With CGRP function-blocking therapy showing efficacy even in individuals who failed other preventives, it has become an exciting new therapeutic option in the field of migraine and CH. SN - 1526-4610 UR - https://www.unboundmedicine.com/medline/citation/31291020/Targeting_CGRP_for_the_Prevention_of_Migraine_and_Cluster_Headache:_A_Narrative_Review_ L2 - https://doi.org/10.1111/head.13583 DB - PRIME DP - Unbound Medicine ER -